Suchergebnisse
Suchergebnisse:
Vor 2 Tagen · 8098 Background: In recent years, the use of immune checkpoint inhibitors has led to significant progress in the treatment of extensive-stage small cell lung cancer. However, there is limited data on the efficacy of immunotherapy in patients with limited-stage disease (LS-SCLC). Therefore, we conducted a phase II randomized study to verify the efficacy and safety of Toripalimab consolidation ...
Vor 2 Tagen · NHC Key Laboratory of Clinical Nephrology (Sun Yat-sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou 510080, China Search for articles by this author Show footnotes Hide footnotes
Vor 22 Stunden · Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, People’s Republic of China. Ming Li, Zhongyu Xie, Peng Wang, Jinteng Li, Wenjie Liu, Su’an ...
Vor 2 Tagen · 3566 Background: In several clinical studies, the combination of anti-programmed cell death protein 1 (anti-PD-1) antibodies with targeted antiangiogenic agents has demonstrated clinical benefits for patients with metastatic colorectal cancer (mCRC). However, individuals with liver metastases have shown suboptimal responses. Prior preclinical study indicates a synergistic efficacy of ...
Vor 2 Tagen · 4123 Background: The current standard treatment for initially unresectable hepatocellular carcinoma (uHCC) is transarterial chemoembolization (TACE) or systemic treatments, but these approaches led to poor conversion resection rate. We aimed to investigate the clinical activity and safety of downstage conversion therapy with Sintilimab, a PD-1 inhibitor, Lenvatinib and TACE- HAIC (hepatic ...
Vor 3 Tagen · Department of Rehabilitation Medicine, The Third Affiliated Hospital, Sun Yat-sen University, 600 Tianhe Road, Guangzhou, 510630, Guangdong, China. 申请注册联系人邮政编码： Applicant postcode： 研究负责人邮政编码： Study leader's postcode： 申请人所在单位：
Vor 2 Tagen · Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong, China
